PMID- 32082329
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in 
      Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD).
PG  - 81
LID - 10.3389/fimmu.2020.00081 [doi]
LID - 81
AB  - As the use of hematopoietic stem cell transplantation (HSCT) has become a more 
      widespread and effective treatment for hematological malignant and non-malignant 
      conditions, the need to minimize the harmful effects of graft- vs.-host disease 
      (GvHD) has become more important in achieving good outcomes. With diagnosis of 
      GvHD reliant on its clinical manifestations, research into biomarkers for the 
      diagnosis, progression, and even for the prediction of disease, is imperative to 
      combating the high levels of morbidity and mortality post-HSCT. Despite the 
      development of novel treatment approaches to GvHD, corticosteroids remain the 
      standard first-line treatment, with immunosuppressant therapies as second-line 
      options. These strategies however have significant limitations and associated 
      complications. Extracorporeal Photopheresis (ECP) has shown to be effective and 
      safe in treating patients with symptomatic GvHD. ECP has been shown to have 
      varied effects on multiple parts of the immune system and does not appear to 
      increase the risk of relapse or infection in the post HSCT setting. Even so, ECP 
      can be logistically more complex to organize and requires patients to be 
      sufficiently stable. This review aims to summarize the potential role of 
      biomarkers to help guide individualized treatment decisions in patients with 
      acute and chronic GvHD. In relation to ECP, robust biomarkers of GvHD will be 
      highly useful in informing patient selection, intensity and duration of the ECP 
      schedule, monitoring of response and other treatment decisions alongside the 
      concurrent administration of other GvHD therapies. Further research is warranted 
      to establish how GvHD biomarkers are best incorporated into ECP treatment 
      pathways with the goal of tailoring ECP to the needs of individual patients and 
      maximizing benefit.
CI  - Copyright (c) 2020 Mankarious, Matthews, Snowden and Alfred.
FAU - Mankarious, Matthew
AU  - Mankarious M
AD  - Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, 
      Royal Hallamshire Hospital, Sheffield, United Kingdom.
FAU - Matthews, Nick C
AU  - Matthews NC
AD  - Department of Photopheresis, The Rotherham NHS Foundation Trust, Rotherham, 
      United Kingdom.
FAU - Snowden, John A
AU  - Snowden JA
AD  - Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, 
      Royal Hallamshire Hospital, Sheffield, United Kingdom.
FAU - Alfred, Arun
AU  - Alfred A
AD  - Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, 
      Royal Hallamshire Hospital, Sheffield, United Kingdom.
AD  - Department of Photopheresis, The Rotherham NHS Foundation Trust, Rotherham, 
      United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200131
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Biomarkers)
SB  - IM
MH  - Animals
MH  - *Biomarkers
MH  - Graft vs Host Disease/*drug therapy
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Photopheresis/*methods
PMC - PMC7005102
OTO - NOTNLM
OT  - GvHD
OT  - apoptosis
OT  - biomarkers
OT  - dendritic cells
OT  - extracorporeal photopheresis
OT  - immunomodulation
EDAT- 2020/02/23 06:00
MHDA- 2021/04/07 06:00
PMCR- 2020/01/01
CRDT- 2020/02/22 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/01/13 00:00 [accepted]
PHST- 2020/02/22 06:00 [entrez]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.00081 [doi]
PST - epublish
SO  - Front Immunol. 2020 Jan 31;11:81. doi: 10.3389/fimmu.2020.00081. eCollection 
      2020.